NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts rate NewAmsterdam Pharma “Moderate Buy.” Ten of 13 analysts recommend buying the stock, with an average 12-month price target of $49.73 versus its recent $22.80 share price.
• Insiders have recently reduced their holdings. Company insiders sold 271,600 shares worth approximately $7.8 million over the past 90 days, while institutional investors own 89.89% of the stock.
• The company remains unprofitable but exceeded revenue expectations. NewAmsterdam reported a quarterly loss of $0.52 per share, missing estimates by $0.04, while revenue of $3.7 million surpassed the $2.83 million consensus forecast.

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $49.7273.

NAMS has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday. Jefferies Financial Group restated a "buy" rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They set an "outperform" rating and a $58.00 target price for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Finally, Royal Bank Of Canada decreased their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 125,000 shares of the business's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the completion of the transaction, the insider owned 69,302 shares of the company's stock, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Louise Kooij sold 105,000 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company's stock, valued at $738,870.02. This trade represents a 81.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 271,600 shares of company stock valued at $7,797,962 over the last ninety days. 12.74% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in NAMS. Wells Fargo & Company MN lifted its stake in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV acquired a new stake in NewAmsterdam Pharma in the first quarter valued at approximately $37,000. Navalign LLC bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $46,000. AdvisorNet Financial Inc bought a new stake in shares of NewAmsterdam Pharma during the first quarter worth $82,000. Finally, Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth $85,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Stock Up 4.3%

Shares of NewAmsterdam Pharma stock opened at $22.80 on Friday. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of -10.56 and a beta of 0.09. NewAmsterdam Pharma has a 12-month low of $21.23 and a 12-month high of $42.21. The firm's 50-day moving average price is $28.60 and its two-hundred day moving average price is $31.22.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -1.82 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.